|Articles|November 15, 2016

SCRS Welcomes GlaxoSmithKline as a Global Impact Partner

The Society for Clinical Research Sites (SCRS) has announced GlaxoSmithKline (GSK) as its newest Global Impact Partner (GIP).

The Society for Clinical Research Sites (SCRS) has announced GlaxoSmithKline (GSK) as its newest Global Impact Partner (GIP). As a GIP, GSK will serve on the SCRS Global Impact Board and work closely with the organization’s Leadership Council on setting and working toward strategic initiatives.

Read the full release here

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
September 15th 2025
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
September 15th 2025
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
September 15th 2025
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
September 15th 2025
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025

Trending on Applied Clinical Trials Online

Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer

Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome

ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research

Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease

NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG

© 2025 MJH Life Sciences^®

All rights reserved.